… treatment of an anti-EpCAM neutralizing antibody (EpAb2-6) and an HGFR inhibitor (crizotinib)
significantly inhibits tumor … in metastatic and orthotopic animal models of colon cancer. …

… an anti‑EpCAM monoclonal antibody (mAb) for targeting … a novel anti-EpCAM mAb may be
useful for treating colorectal … xenograft model, they demonstrated that EpAb2-6 induced CRC …

… model of metastatic colon carcinoma to test whether EpAb2-6 treatment could increase the
… We have previously demonstrated that anti-EpCAM neutralizing antibody, EpAb2-6, could …

… Our humanized anti-EpCAM antibody hEpAb2-6 blocks these … As such, the EpCAM-neutralizing
antibody, EpAb2-6, was … anti-EpCAM therapeutics may be effective for the treatment …

… EpAb2-6—a mouse antibody—is the first antibody class … mAbs, and it has been approved
for the treatment of malignant … cytotoxicity against the human colon cancer cell line HCT116, …

… against the EpCAM molecule, called Edrecolomab with the Panorex brand, is a mouse
IgG2a type used to treat colon cancer. However, it had a series of disadvantages (abdominal …

… in leukemia and colon cancer [13, 19]. In early esophageal cancer, decreased expression of
… , therapeutic methods targeting EpCAM have shown potential for cancer treatment [23, 24]. …

… is the human anti-EpCAM monoclonal IgG1 antibody, Adecatumumab … EpAb2-6, an
EpCAM-neutralizing antibody, has shown … era in the management of colorectal cancer, bringing …

… Anti-EpCAM antibodies were developed and used for the treatment of colon cancer [61],
metastatic breast cancer [… the treatment of tumors, sometimes making tumor cells resistant to the …

… antibody 1083-17-1A (Co17-1A or mAb 17-1A) following inoculation of human colorectal
cancer … Panorex® (edrecolomab; 17-1A) first attained market approval for treating colorectal …